Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population

References

• World Health Organization: Chronic obstructive pulmonary disease (COPD). Available at: http://www.who.int/respiratory/copd/en [Last accessed 10 December 2008]
   Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance – United States, 1971-2000. MMWR Surveill Summ 2002;51:1-16
   PubMed Web of Science ®Google Scholar
• American Lung Association Epidemiology & Statistics Unit Research and Program Services. Trends in Chronic Obstructive Bronchitis and Emphysema: Morbidity and Mortality. Available at: http://www.lungusa.org/atf/cf/%7B7a8d42c2-fcca-4604-8ade-7f5d5e762256%7D/COPD_DEC07.PDF [Last accessed 10 December 2008]
   Google Scholar
• Eisner MD, Yelin EH, Trupin L, et al. The influence of chronic respiratory conditions on health status and work disability. Am J Public Health 2002;92:1506-13
   PubMed Web of Science ®Google Scholar
• Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003;22:462-9
   PubMed Web of Science ®Google Scholar
• Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med 2003;97(Suppl C):S81-9
   PubMed Web of Science ®Google Scholar
• Tinkelman D, Nordyke RJ, Isonaka S, et al. The impact of chronic obstructive pulmonary disease on long-term disability costs. J Manag Care Pharm 2005;1:25-32
   Google Scholar
• Centers for Disease Control and Prevention: National Center for Health Statistics: National Hospital Discharge Survey, 1979-2004, 2005 unpublished data provided upon special request. [Note: Accessed through Reference #3]
   Google Scholar
• Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005-11
   PubMed Web of Science ®Google Scholar
• Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459-67
   PubMed Web of Science ®Google Scholar
• Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-67
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. Morbidity and mortality: 2007 chartbook on cardiovascular, lung, and blood diseases. Available at: http://www.nhlbi.nih.gov/resources/docs/07a-chtbk.pdf [Last accessed 20 January 2009]
   Google Scholar
• Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2008). Available at: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003 [Last accessed 18 January 2009]
   Google Scholar
• American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. Available at: http://www.thoracic.org/sections/copd/index.html [Last accessed 19 January 2009]
   Google Scholar
• Kunisaki KM, Rice KL, Niewoehner DE. Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly: an appraisal of published evidence. Drugs Aging 2007;24:303-24
   PubMed Web of Science ®Google Scholar
• Yohannes AM, Hardy CC. Treatment of chronic obstructive pulmonary disease in older patients: a practical guide. Drugs Aging 2003;20:209-28
   PubMed Web of Science ®Google Scholar
• Stuart B, Simoni-Wastila L, Zuckerman IH, et al. Medication use by aged and disabled Medicare beneficiaries across the spectrum of morbidity – a Chartbook. The Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy, Baltimore, MD. Available at: http://www.pharmacy.umaryland.edu/lamy/Complete%20Chartbook%20w.%20cover.pdf [Last accessed 15 July 2009]
   Google Scholar
• Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008;102:1248-56
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Gutierrez B, Ory C, et al. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008;14:176-85
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;2:74-81
   Google Scholar
• Akazawa M, Hayflinger DC, Stanford RH, et al. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008;14:438-48
   PubMed Web of Science ®Google Scholar
• Rascati KL, Akazawa M, Johnsrud M, et al. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther 2007;29:1203-13
   PubMed Web of Science ®Google Scholar
• Shaya FT, Dongyi D, Akazawa MO, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest 2008;134:14-19
   PubMed Web of Science ®Google Scholar
• Akazawa M, Stearns SC, Biddle AK. Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. Health Serv Res 2008;43:2164-82
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Akazawa M, Dalal A, et al. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults. Am J Geriatr Pharmacother 2008;6:138-46
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar